Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 2 February 2021 regarding the exercise of share options and
the share capital increase pertaining thereto.  
The share capital increase of NOK 1,666.24 divided on 83,312 shares has today
been registered in the Norwegian Register of Business Enterprises (Nw:
Foretaksregisteret).  

Following the share capital increase, the new share capital in the Company is
NOK 176,446.04 divided into 8,822,302 shares, each with a nominal value of NOK
0.02. 

The new shares will be listed and tradable on Euronext Growth Oslo from issuance
in the Central Securities Depository (VPS).

The shares issued on 4 March 2021 in relation to the subsequent offering and the
shares issued on 24 February 2021 in relation to the employee offering are
expected to be registered in the Norwegian Register of Business Enterprises (Nw:
Foretaksregisteret) on or about 17 March 2021, and will delivered in the Central
Securities Depository (VPS) as soon as possible following the registration.  

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or
Kritine Rød, Finance Manager of SoftOx Solutions AS
Mail: ir@soft-ox.com 
Mobile: +47 977 59 071

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
MedTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com